Results 81 to 90 of about 10,197,473 (297)

The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer

Molecular Oncology, EarlyView.
Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad, Silvio Carlo Ermanno Tosatto, Emanuela Leonardi   +2 more
wiley   +1 more source

The roles of Fibroblast Growth Factor 22 in development, tissue repair and homeostasis, and the associated role of FGF signalling in skin cancer. [PDF]

, 2010
PhDFibroblast Growth Factors (FGFs) play critical roles during development, tissue homeostasis and repair and in controlling cell proliferation, survival, migration and differentiation.
Jarosz, Monika
core   +2 more sources

Farnesoid X Receptor Regulated Sepsis‐Induced Abnormal Bile Acid Metabolism via the Fibroblast Growth Factor 15/Fibroblast Growth Factor Receptor 4 Pathway

Immunity, Inflammation and Disease
Objective The study aims to investigate the mechanism of Farnesoid X receptor (FXR) activation in sepsis‐induced abnormal bile acid metabolism and the metabolism status of each bile acid type.
Ziyang Zhou, Dan Xu, Liou Huang, Yuhui Cui, Hui Chen, Jianguo Tang   +5 more
doaj   +1 more source

Phosphorus Restriction Changes the Expression of Fibroblast Growth Factor 23 and Its Receptors in Laying Hens

Frontiers in Physiology, 2020
Dietary phosphorus oversupply wastes non-renewable natural resources and raises environmental concerns in animal agriculture. We hypothesized that laying hens do not need large safety margins for dietary phosphorus because of the existence of fibroblast ...
Zhouzheng Ren, Jiakun Yan, Qianli Hu, Xinshuai Liu, Chong Pan, Yanli Liu, Xiaozhen Zhang, Xin Yang, Xiaojun Yang   +8 more
doaj   +1 more source

Supplementary Data from Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma

, 2009
Supplementary Data from Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in ...
Michael G. Gartside (14889647), Ana Bengston (14892053), Pilar Hyder (15085092), Graham J. Mann (6174710), Huaibin Chen (15085080), Moosa Mohammadi (88381), Pamela M. Pollock (14871696), Boris C. Bastian (12883149), Laura M. Yudt (15085089), Candice L. Wellens (14889650), Ursula L. Harper (2817598), Jeffrey M. Trent (9110592), Jinghong Ma (1755838), Amy V. Curtis (15085086), John A. Curtin (9510637), Erica Riedesel (15085095), Sara A. Byron (8195817), Paul S. Meltzer (8423274), Omar A. Ibrahimi (15085083), Anna V. Eliseenkova (2351683)   +19 more
core   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

Biology of FGFRL1, the fifth fibroblast growth factor receptor [PDF]

, 2010
FGFRL1 (fibroblast growth factor receptor like 1) is the most recently discovered member of the FGFR family. It contains three extracellular Ig-like domains similar to the classical FGFRs, but it lacks the protein tyrosine kinase domain and instead ...
Trueb, Beat, Beat Trueb, Trueb B
core   +2 more sources

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies.

, 2007
Basic fibroblast growth factor/fibroblast growth factor-2 is one of the best characterized of the pro-angiogenic cytokines. This review describes its history, as well as its role in tumor angiogenesis associated with haematological malignancies, as ...
RUSNATI, Marco, VACCA A, RIBATTI D, PRESTA, Marco   +3 more
core   +1 more source